Preview

 Пульмонология

Расширенный поиск

Обострение идиопатического легочного фиброза

https://doi.org/10.18093/0869-0189-2018-28-4-469-482

Полный текст:

Аннотация

Обострение идиопатического легочного фиброза (ИЛФ) определяется как острое, клинически значимое респираторное ухудшение, обычно развивающееся в сроки < 1 мес.,  характеризующееся при проведении компьютерной томографии высокого разрешения  новыми изменениями, такими как диффузные двусторонние изменения по типу матового  стекла и / или консолидаты, а также отсутствием других явных клинических причин  ухудшения – перегрузка объемом, сердечная недостаточность, тромбоэмболия легочной  артерии и т. п. Обострения ИЛФ подразделяются на «вызванные», т. е. имеющие причины  (например, инфекции, хирургические операции, лекарственная токсичность и др.), и  идиопатические обострения – случаи, где причину установить не удается. По результатам  рандомизированных исследований 1-годичная заболеваемость обострением ИЛФ составляет около 8 %, а по результатам ретроспективных исследований – 19 %. Важным фактором  риска развития обострений ИЛФ являются тяжелые формы ИЛФ. Внутригоспитальная  летальность при обострении ИЛФ составляет > 50 %, а средняя выживаемость больных  после обострения ИЛФ – 1–4 мес. В настоящее время методы терапии, эффективность  которых была бы доказана при обострении ИЛФ, отсутствуют. В реальной клинической  практике пациентам с обострением ИЛФ чаще всего назначаются глюкокортикостероиды в  высоких дозах и антибактериальные препараты. Риск развития обострений уменьшается  при назначении антифибротической терапии, а при терапии нинтеданибом число  подтвержденных / подозреваемых обострений ИЛФ снижается на 68 %. Отмечается  необходимость дальнейшего изучения потенциальных методов профилактики и терапии обострений ИЛФ в клинических исследованиях.

Об авторе

С. Н. Авдеев
Федеральное государственное бюджетное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства здравоохранения Российской Федерации Федеральное государственное бюджетное учреждение «Научно-исследовательский институт пульмонологии» Федерального медико-биологического агентства
Россия

д. м. н., член-корр. Российской академии наук, профессор, заведующий кафедрой пульмонологии Федерального государственного бюджетного образовательного учреждения высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства  здравоохранения Российской Федерации, руководитель  клинического отдела Федерального государственного бюджетного учреждения «Научно- исследовательский институт пульмонологии» Федерального  медико-биологического агентства

тел.: (495) 395-63-93

119991, Москва, ул. Трубецкая, 8, стр. 2

115682, Москва, Ореховый бульвар, 28



Список литературы

1. Raghu G., Collard H.R., Egan J.J. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183 (6): 788–824. DOI: 10.1164/rccm.2009-040GL.

2. Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Диагностика и лечение идиопатического легочного фиброза. Федеральные клинические рекомендации. Пульмонология. 2016; 26 (4): 399–419. DOI: 10.18093/0869-0189-2016-26-4-399-419.

3. Авдеев С. Н. Идиопатический легочный фиброз: новая парадигма. Терапевтический архив. 2017; 89 (1): 112–122. DOI: 10.17116/terarkh2017891112-122.

4. Bjoraker J.A., Ryu J.H., Edwin M.K. et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998; 157 (1): 199–203. DOI: 10.1164/ajrccm.157.1.9704130.

5. Ley B., Ryerson C.J., Vittinghoff E. et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med. 2012; 156 (10): 684–691. DOI: 10.7326/0003-4819-156-10-201205150-00004.

6. Martinez F.J., Safrin S., Weycker D. et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann. Intern. Med. 2005; 142 (12, Pt 1): 963–967.

7. King T.E. Jr, Albera C., Bradford W.Z. et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am. J. Respir. Crit. Care Med. 2014; 189 (7): 825–831. DOI: 10.1164/rccm.201311-1951OC.

8. Kondoh Y., Taniguchi H., Kawabata Y. et al. Acute exacerbation in idiopathic pulmonary fibrosis: analysis of clinical and pathological findings in three cases. Chest. 1993; 103 (6): 1808–1812. DOI: 10.1378/chest.103.6.1808.

9. Авдеев С.Н., Черняев А.Л., Самсонова М.В., Мержоева З.М. Обострение идиопатического легочного фиброза. Пульмонология. 2006; (4): 123–127.

10. Ambrosini V., Cancellieri A., Chilosi M. et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur. Respir. J. 2003; 22 (5): 821–826. DOI: 10.1183/09031936.03.00022703.

11. Collard H.R., Moore B.B., Flaherty K.R. et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2007; 176 (7): 636–643. DOI: 10.1164/rccm.200703-463PP.

12. Leuschner G., Behr J. Acute exacerbation in interstitial lung disease. Front. Med. 2017; 4. DOI: 10.3389/fmed.2017.00176.

13. Collard H.R., Ryerson C.J., Corte T.J. et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am. J. Respir. Crit. Care Med. 2016; 194 (3): 265–275. DOI: 10.1164/rccm.201604-0801CI.

14. Kim D.S., Park J.H., Park B.K. et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur. Respir. J. 2006; 27 (1): 143–150. DOI: 10.1183/09031936.06.00114004.

15. Song J.W., Hong S.B., Lim C.M. et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur. Respir. J. 2011; 37 (2): 356–363. DOI: 10.1183/09031936.00159709.

16. Akira M., Hamada H., Sakatani M. et al. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. Am. J. Roentgenol. 1997; 168 (1): 79–83. DOI: 10.2214/ajr.168.1.8976924.

17. Kishaba T., Tamaki H., Shimaoka Y. et al. Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis. Lung. 2014; 192 (1): 141–149. DOI: 10.1007/s00408-013-9530-0.

18. Akira M., Kozuka T., Yamamoto S., Sakatani M. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2008; 178 (4): 372–378. DOI: 10.1164/rccm.200709-1365OC.

19. Fujimoto K., Taniguchi H., Johkoh T. et al. Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality. Eur. Radiol. 2012; 22 (1): 83–92. DOI: 10.1007/s00330-011-2211-6.

20. Usui Y., Kaga A., Sakai F. et al. A cohort study of mortality predictors in patients with acute exacerbation of chronic fibrosing interstitial pneumonia. Br. Med. J. Open. 2013; 3 (7): pii: e002971. DOI: 10.1136/bmjopen-2013-002971.

21. Parambil J.G., Myers J.L., Ryu J.H. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis under-going surgical lung biopsy. Chest. 2005; 128: 3310–3315. DOI: 10.1136/bmjopen-2013-002971.

22. Черняев А.Л., Самсонова М.В. Диффузное альвеолярное повреждение: этиология, патогенез и патологическая анатомия. Пульмонология. 2005; (4): 65–69.

23. Churg A., Muller N.L., Silva C.I., Wright J.L. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am. J. Surg. Pathol. 2007; 31 (2): 277–284. DOI: 10.1097/01.pas.0000213341.70852.9d.

24. Dallari R., Foglia M., Paci M., Cavazza A. Acute exacerbation of idiopathic pulmonary fibrosis. Eur. Respir. J. 2004; 23 (5): 792. DOI: 10.1183/09031936.04.00004404.

25. Collard H.R., Calfee C.S., Wolters P.J. et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010; 299 (1): L3–7. DOI: 10.1152/ajplung.90637.2008.

26. Ohshimo S., Ishikawa N., Horimasu Y. et al. Baseline KL-6 predicts increased risk for acute exacerbation of idio-pathic pulmonary fibrosis. Respir. Med. 2014; 108 (7): 1031–1039. DOI: 10.1016/j.rmed.2014.04.009.

27. Kishaba T., Shimaoka Y., Fukuyama H. et al. A cohort study of mortality predictors and characteristics of patients with combined pulmonary fibrosis and emphysema. Br. Med. J. Open. 2012; 2 (3): e000988. DOI: 10.1136/bmjopen-2012-000988.

28. Arcadu A., Moua T. Bronchoscopy assessment of acute respiratory failure in interstitial lung disease. Respirology. 2017; 22 (2): 352–359. DOI: 10.1111/resp.12909.

29. Takei R., Arita M., Kumagai S. et al. Impact of lymphocyte differential count > 15 % in BALF on the mortality of patients with acute exacerbation of chronic fibrosing idiopathic interstitial pneumonia. BMC. Pulm. Med. 2017; 17 (1): 67. DOI: 10.1186/s12890-017-0412-8.

30. Ryerson C.J., Cottin V., Brown K.K., Collard H.R. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur. Respir. J. 2015; 46 (2): 512–520. DOI: 10.1183/13993003.00419-2015.

31. Collard H.R., Yow E., Richeldi L. et al. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir. Res. 2013; (14): 73. DOI: 10.1186/1465-9921-14-73.

32. Atkins C.P., Loke Y.K., Wilson A.M. Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials. Respir. Med. 2014; 108 (2): 376–387. DOI: 10.1016/j.rmed.2013.11.007.

33. Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370 (22): 2071–2082. DOI: 10.1056/NEJMoa1402584.

34. Kondoh Y., Taniguchi H., Katsuta T. et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2010; 27 (2): 103–110.

35. Johannson K.A., Vittinghoff E., Lee K. et al. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur. Respir. J. 2014; 43 (4): 1124–1131. DOI: 10.1183/09031936.00122213.

36. Kondoh Y., Taniguchi H., Ebina M. et al. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis – extended analysis of pirfenidone trial in Japan. Respir. Investig. 2015; 53 (6): 271–278. DOI: 10.1016/j.resinv.2015.04.005.

37. Sakamoto S., Homma S., Mun M. et al. Acute exacerbation of idiopathic interstitial pneumonia following lung surgery in 3 of 68 consecutive patients: a retrospective study. Intern. Med. 2011; 50 (2): 77–85. DOI: 10.2169/internalmedicine.50.3390.

38. Samejima J., Tajiri M., Ogura T. et al. Thoracoscopic lung biopsy in 285 patients with diffuse pulmonary disease. Asian Cardiovasc. Thorac. Ann. 2015; 23 (2): 191–197. DOI: 10.1177/0218492314550724.

39. Rotolo N., Imperatori A., Dominioni L. et al. Efficacy and safety of surgical lung biopsy for interstitial disease. Experience of 161 consecutive patients from a single institution in Italy. Sarcoidosis Vasc. Diffuse Lung Dis. 2015; 32 (3): 251–258.

40. Bando M., Ohno S., Hosono T. et al. Risk of acute exacerbation after video-assisted thoracoscopic lung biopsy for interstitial lung disease. J. Bronchology Interv. Pulmonol. 2009; 16 (4): 229–235. DOI: 10.1097/LBR.0b013e3181b767cc.

41. Taniguchi H., Ebina M., Kondoh Y. et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 35 (4): 821–829. DOI: 10.1183/09031936.00005209.

42. Costabel U., Inoue Y., Richeldi L. et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am. J. Respir. Crit. Care Med. 2016; 193 (2): 178–185. DOI: 10.1164/rccm.201503-0562OC.

43. Kuhn C. 3rd, Boldt J., King T.E. Jr et al. An immunohistochemical study of architectural remodeling and connective tis-sue synthesis in pulmonary fibrosis. Am. Rev. Respir. Dis. 1989; 140 (6): 1693–1703. DOI: doi.org/10.1164/ajrccm/140.6.1693.

44. Konishi K., Gibson K.F., Lindell K.O. et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 180 (2): 167–175. DOI: 10.1164/rccm.200810-1596OC.

45. Mukae H., Iiboshi H., Nakazato M. et al. Raised plasma concentrations of alpha-defensins in patients with idiopathic pulmonary fibrosis. Thorax. 2002; 57 (7): 623–628. DOI: 10.1136/thorax.57.7.623.

46. van Wetering S., Sterk P.J., Rabe K.F., Hiemstra P.S. Defensins: key players or bystanders in infection, injury, and repair in the lung? J. Allergy Clin. Immunol. 1999; 104 (6): 1131–1138. DOI: 10.1016/S0091-6749(99)70004-7.

47. Ganz T., Lehrer R.I. Defensins. Curr. Opin. Immunol. 1994; 6 (4): 584–589. DOI: 10.1016/0952-7915(94)90145-7.

48. Moeller A., Gilpin S.E., Ask K. et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 179 (7): 588–594. DOI: 10.1164/rccm.200810-1534OC.

49. Bucala R., Spiegel L.A., Chesney J. et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1994; 1 (1): 71–81.

50. Gomperts B.N., Strieter R.M. Fibrocytes in lung disease. J. Leukoc. Biol. 2007; 82 (3): 449–456. DOI: 10.1189/jlb.0906587.

51. Mantovani A., Sica A., Sozzani S. et al. The chemo-kine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25 (12): 677–686. DOI: 10.1016/j.it.2004.09.015.

52. Schupp J.C., Binder H., Jager B. et al. Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis. PLoS One. 2015; 10 (1): e0116775. DOI: 10.1371/journal.pone.0116775.

53. Ushiki A., Yamazaki Y., Hama M. et al. Viral infections in patients with an acute exacerbation of idiopathic interstitial pneumonia. Respir. Investig. 2014; 52 (1): 65–70. DOI: 10.1016/j.resinv.2013.07.005.

54. Wootton S.C., Kim D.S., Kondoh Y. et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 183 (12): 1698–1702. DOI: 10.1164/rccm.201010-1752OC.

55. Huie T.J., Olson A.L., Cosgrove G.P. et al. A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology. 2010; 15 (6): 909–917. DOI: 10.1111/j.1440-1843.2010.01774.x.

56. Molyneaux P.L., Cox M.J., Wells A.U. et al. Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir. Res. 2017; 18 (1): 29. DOI: 10.1186/s12931-017-0511-3.

57. Simon-Blancal V., Freynet O., Nunes H. et al. Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors. Respiration. 2012; 83 (1): 28–35. DOI: 10.1159/000329891.

58. Petrosyan F., Culver D.A., Reddy A.J. Role of bronchoalveolar lavage in the diagnosis of acute exacerbations of idiopathic pulmonary fibrosis: a retrospective study. BMC. Pulm. Med. 2015; (15): 70. DOI: 10.1186/s12890-015-0066-3.

59. Lee J.S., Collard H.R., Anstrom K.J. et al. Anti–acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet. Respir. Med. 2013; 1 (5): 369–376. DOI: 10.1016/S2213-2600(13)70105-X.

60. Lee J.S., Song J.W., Wolters P.J. et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur. Respir. J. 2012; 39 (2): 352–358. DOI: 10.1183/09031936.00050911.

61. Mizuno Y., Iwata H., Shirahashi K. et al. The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer. Eur. J. Cardiothorac. Surg. 2012; 41 (6): e161–165. DOI: 10.1093/ejcts/ezs147.

62. Suzuki H., Sekine Y., Yoshida S. et al. Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography. Surg. Toda. 2011; 41 (7): 914–921. DOI: 10.1007/s00595-010-4384-z.

63. Watanabe A., Higami T., Ohori S. et al. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? J. Thorac. Cardiovasc. Surg. 2008; 136 (5): 1357–1363.e2. DOI: 10.1016/j.jtcvs.2008.07.016.

64. Park J.S., Kim H.K., Kim K. et al. Prediction of acute pulmonary complications after resection of lung cancer in patients with preexisting interstitial lung disease. Thorac. Cardiovasc. Surg. 2011; 59 (3): 148–152. DOI: 10.1055/s-0030-1250644.

65. Ghatol A., Ruhl A.P., Danoff S.K. Exacerbations in idiopathic pulmonary fibrosis triggered by pulmonary and nonpulmonary surgery: a case series and comprehensive review of the literature. Lung. 2012; 190 (4): 373–380. DOI: 10.1007/s00408-012-9389-5.

66. Choi S.M., Lee J., Park Y.S. et al. Postoperative pulmonary complications after surgery in patients with interstitial lung disease. Respiration. 2014; 87 (4): 287–293. DOI: 10.1159/000357046.

67. Hiwatari N., Shimura S., Takishima T., Shirato K. Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients. Tohoku J. Exp. Med. 1994; 174 (4): 379–386. DOI: 10.1620/tjem.174.379.

68. Sakamoto K., Taniguchi H., Kondoh Y. et al. Acute exacerbation of IPF following diagnostic bronchoalveolar lavage procedures. Respir. Med. 2012; 106 (3): 436–442. DOI: 10.1016/j.rmed.2011.11.006.

69. Tomic R., Cortes-Puentes G.A., Murugan P. et al. Acute exacerbation of interstitial lung disease after cryobiopsy. J. Bronchology Interv. Pulmonol. 2017; 24 (4): 319–322. DOI: 10.1097/LBR.0000000000000369.

70. Casoni G.L., Tomassetti S., Cavazza A. et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS One. 2014; 9 (2): e86716. DOI: 10.1371/journal.pone.0086716.

71. Selman M., Carrillo G., Estrada A. et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One. 2007; 2 (5): e482. DOI: 10.1371/journal.pone.0000482.

72. Russell A.M., Adamali H., Molyneaux P.L. et al. Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2016; 194 (8): 989–997. DOI: 10.1164/rccm.201511-2152OC.

73. Judge E.P., Fabre A., Adamali H.I., Egan J.J. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur. Respir. J. 2012; 40 (1): 93–100. DOI: 10.1183/09031936.00115511.

74. Ohshimo S., Ishikawa N., Horimasu Y. et al. Baseline KL-6 predicts increased risk for acute exacerbation of idio-pathic pulmonary fibrosis. Respir. Med. 2014; 108 (7): 1031–1039. DOI: 10.1016/j.rmed.2014.04.009.

75. Horita N., Akahane M., Okada Y. et al. Tacrolimus and steroid treatment for acute exacerbation of idiopathic pulmonary fibrosis. Intern. Med. 2011; 50 (3): 189–195. DOI: 10.2169/internalmedicine.50.4327.

76. Kakiuchi S., Hanibuchi M., Tezuka T. et al. Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: a feasibility of S-1. Respir. Investig. 2017; 55 (2): 145–152. DOI: 10.1016/j.resinv.2016.10.008.

77. Takeda A., Enomoto T., Sanuki N. et al. Acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by hypofractionated stereotactic body radiotherapy in a patient with primary lung cancer and slightly focal honeycombing. Radiat. Med. 2008; 26 (8): 504–507. DOI: 10.1007/s11604-008-0261-8.

78. Parambil J.G., Myers J.L., Aubry M.C., Ryu J.H. Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy. Chest. 2007; 132 (1): 50–57. DOI: 10.1378/chest.07-0104.

79. Jeon K., Chung M.P., Lee K.S. et al. Prognostic factors and causes of death in Korean patients with idiopathic pulmonary fibrosis. Respir. Med. 2006; 100 (3): 451–457. DOI: 10.1016/j.rmed.2005.06.013.

80. Seo Y., Abe S., Kurahara M. et al. Beneficial effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on acute exacerbation of idiopathic pulmonary fibrosis. Intern. Med. 2006; 45 (18): 1033–1038. DOI: 10.2169/internalmedicine.45.6018.

81. Tachikawa R., Tomii K., Ueda H. et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic. Respiration. 2012; 83 (1): 20–27. DOI: 10.1159/000329893.

82. Olson A.L., Huie T.J., Groshong S.D. et al. Acute exacerbations of fibrotic hypersensitivity pneumonitis: a case series. Chest. 2008; 134 (4): 844–850. DOI: 10.1378/chest.08-0428.

83. Suda T., Kaida Y., Nakamura Y. et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir. Med. 2009; 103 (6): 846–853. DOI: 10.1016/j.rmed.2008.12.019.

84. Miyazaki Y., Tateishi T., Akashi T. et al. Clinical predictors and histologic appearance of acute exacerbations in chronic hypersensitivity pneumonitis. Chest. 2008; 134 (6): 1265–1270. DOI: 10.1378/chest.08-0866.

85. Kahloon R.A., Xue J., Bhargava A. et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am. J. Respir. Crit. Care Med. 2013; 187 (7): 768–775. DOI: 10.1164/rccm.201203-0506OC.

86. Morell F., Esser D., Lim J. et al. Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain–results of a Delphi Panel. BMC. Pulm. Med. 2016; (16): 7. DOI: 10.1186/s12890-016-0168-6.

87. Yu Y.F., Wu N., Chuang C.C. et al. Patterns and economic burden of hospitalizations and exacerbations among patients diagnosed with idiopathic pulmonary fibrosis. J. Manag. Care Spec. Pharm. 2016; 22 (4): 414–423. DOI: 10.18553/jmcp.2016.22.4.414.

88. Bozso S., Sidhu S., Garg M. et al. Canada’s longest experience with extracorporeal membrane oxygenation as a bridge to lung transplantation: a case report. Transplant. Proc. 2015; 47 (1): 186–189. DOI: 10.1016/j.transproceed.2014.10.039.

89. Rush B., Wiskar K., Berger L., Griesdale D. The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: a nationwide retrospective cohort analysis. Respir. Med. 2016; (111): 72–76. DOI: 10.1016/j.rmed.2015.12.005.

90. Inase N., Sawada M., Ohtani Y. et al. Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern. Med. 2003; 42 (7): 565–570. DOI: 10.2169/internalmedicine.42.565.

91. Homma S., Sakamoto S., Kawabata M. et al. Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia. Intern. Med. 2005; 44 (11): 1144–1150. DOI: 10.2169/internalmedicine.44.1144.

92. Sakamoto S., Homma S., Miyamoto A. et al. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Intern. Med. 2010; 49 (2): 109–115. DOI: 10.2169/internalmedicine.49.2359.

93. Donahoe M., Valentine V.G., Chien N. et al. Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis. PLoS One. 2015; 10 (6): e0127771. DOI: 10.1371/journal.pone.0127771.

94. Abe S., Azuma A., Mukae H. et al. Polymyxin B-immobilized fiber column (PMX) treatment for idiopathic pulmonary fibrosis with acute exacerbation: a multicenter retrospective analysis. Intern. Med. 2012; 51 (12): 1487–1491. DOI: 10.2169/internalmedicine.51.6965.

95. Oishi K., Aoe K., Mimura Y. et al. Survival from an acute exacerbation of idiopathic pulmonary fibrosis with or without direct hemoperfusion with a polymyxin B-immobilized fiber column: a retrospective analysis. Intern. Med. 2016; 55 (24): 3551–3359. DOI: 10.2169/internalmedicine.55.6056.

96. Oishi K., Mimura-Kimura Y., Miyasho T. et al. Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis. Cytokine. 2013; 61 (1): 84–89. DOI: 10.1016/j.cyto.2012.08.032.

97. Isshiki T., Sakamoto S., Kinoshita A. et al. Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study. Respiration. 2015; 89 (3): 201–207. DOI: 10.1159/000369828.

98. Tsushima K., Yamaguchi K., Kono Y. et al. Thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis: a proof of concept study. Pulm. Pharmacol. Ther. 2014; 29 (2): 233–240. DOI: 10.1016/j.pupt.2014.04.008.

99. Kataoka K., Taniguchi H., Kondoh Y. et al. Recombinant human thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2015; 148 (2): 436–443. DOI: 10.1378/chest.14-2746.

100. Hayakawa S., Matsuzawa Y., Irie T. et al. Efficacy of recombinant human soluble thrombomodulin for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a single arm, non-randomized prospective clinical trial. Multidiscip. Respir. Med. 2016; 11: 38. DOI: 10.1186/s40248-016-0074-z.

101. Ding J., Chen Z., Feng K. Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. Int. J. Med. Sci. 2013; 10 (7): 903–907. DOI: 10.7150/ijms.4972.

102. Yokoyama T., Kondoh Y., Taniguchi H. et al. Noninvasive ventilation in acute exacerbation of idiopathic pulmonary fibrosis. Intern. Med. 2010; 49 (15): 1509–1514. DOI: 10.2169/internalmedicine.49.3222.

103. Papiris S.A., Kagouridis K., Kolilekas L. et al. Survival in idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach. BMC. Pulm. Med. 2015; (15): 162. DOI: 10.1186/s12890-015-0146-4.

104. Azuma A., Nukiwa T., Tsuboi E. et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2005; 171 (9): 1040–1047. DOI: 10.1164/rccm.200404-571OC.

105. King T.E. Jr, Bradford W.Z., Castro-Bernardini S. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370 (22): 2083–2092. DOI: 10.1056/NEJMoa1402582.

106. Noble P.W., Albera C., Bradford W.Z. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377 (9779): 1760–1769. DOI: 10.1016/S0140-6736(11)60405-4.

107. Ley B., Swigris J., Day B.M. et al. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2017; 196 (6): 756–761. DOI: 10.1164/rccm.201701-0091OC.

108. Iwata T., Yoshida S., Nagato K. et al. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surg. Today. 2015; 45 (10): 1263–1270. DOI: 10.1007/s00595-014-1071-5.

109. Richeldi L., Costabel U., Selman M. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2011; 365 (12): 1079–1087. DOI: 10.1056/NEJMoa1103690.

110. Collard H.R., Richeldi L., Kim D.S. et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur. Respir. J. 2017; 49 (5): pii: 1601339. DOI: 10.1183/13993003.01339-2016.

111. Martinez F.J., de Andrade J.A., Anstrom K.J. et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370 (22): 2093–2101. DOI: 10.1056/NEJMoa1401739.

112. Zisman D.A., Schwarz M., Anstrom K.J. et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N. Engl. J. Med. 2010; 363 (7): 620–628. DOI: 10.1056/NEJMoa1002110.

113. King T.E. Jr, Brown K.K., Raghu G. et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 184 (1): 92–99. DOI: 10.1164/rccm.201011-1874OC.

114. King T.E. Jr, Albera C., Bradford W.Z. et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009; 374 (9685): 222–228. DOI: 10.1016/S0140-6736(09)60551-1.

115. Noth I., Anstrom K.J., Calvert S.B. et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2012; 186 (1): 88–95. DOI: 10.1164/rccm.201202-0314OC.

116. Raghu G., Behr J., Brown K.K. et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann. Intern. Med. 2013; 158 (9): 641–649. DOI: 10.7326/0003-4819-158-9-201305070-00003.

117. Daniels C.E., Lasky J.A., Limper A.H. et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am. J. Respir. Crit. Care Med. 2010; 181 (6): 604–610. DOI: 10.1164/rccm.200906-0964OC.

118. Raghu G., Anstrom K.J., King T.E. Jr et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366 (21): 1968–1977. DOI: 10.1056/NEJMoa1113354.


Для цитирования:


Авдеев С.Н. Обострение идиопатического легочного фиброза.  Пульмонология. 2018;28(4):469-482. https://doi.org/10.18093/0869-0189-2018-28-4-469-482

For citation:


Avdeev S.N. Acute exacerbation of idiopathic pulmonary fibrosis. Russian Pulmonology. 2018;28(4):469-482. (In Russ.) https://doi.org/10.18093/0869-0189-2018-28-4-469-482

Просмотров: 430


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)